All In Biotech

Free tool

FAERS Monitor: Rylaze

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761179 or its brand name (Rylaze, Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn). Reports on generic versions are filed under their own applications.

Reports

344

Serious

165

48% of reports

Hospitalization

103

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use33
  • hyperammonaemia31
  • febrile neutropenia28
  • nausea26
  • hypersensitivity21
  • pancreatitis20
  • urticaria19
  • rash18
  • vomiting17
  • neutropenia15
  • anaphylactic reaction14
  • ammonia increased12
  • herpes simplex11
  • systemic candida11
  • cerebral candidiasis10

Reports by year received

View as table
YearReports
202244
202369
2024104
202584
202643

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,815 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cerebral candidiasisSignal10122405.942056.8368,231
hyperammonaemiaSignal31381.4272.311,315
systemic candidaSignal11269.1150.22,665
ammonia increasedSignal12144.182.61,562
herpes simplexSignal11103.757.91,017
febrile neutropeniaSignal2825.818.1645
pancreatitisSignal2023.115.1403
anaphylactic reactionSignal1415.59.3176
urticariaSignal196.94.591
hypersensitivitySignal216.94.6101
neutropeniaSignal156.74.168
rashSignal182.51.615
off label useSignal332.31.724
vomitingSignal172.21.410
nauseaSignal262.01.413

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.